IDE892 is a potent and selective MTA-cooperative PRMT5 inhibitor with favorable ADME properties; demonstrating robust MTAP deletion-specific pathway suppression and highly durable antitumor activity ...

NEW YORK--(BUSINESS WIRE)-- Schrödinger (Nasdaq: SDGR) today announced that new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, and the company’s PRMT5-MTA inhibitor program, ...

A new study suggests that blocking an enzyme called PRMT5 in tumor cells could be a promising new strategy for the treatment of glioblastoma (GB), the most aggressive and lethal form of brain cancer.

Dosing of first patient in Phase 1 dose escalation trial of IDE892 targeted in 4Q 2025 Preclinical profile of IDE892 and mechanistic combination rationale with IDE397, IDEAYA's proprietary MAT2A ...

BOSTON, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of ...

The MarketWatch News Department was not involved in the creation of this content. MUMBAI, India, NAPLES, Fla. and CHICAGO, May 27, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) will ...

-- Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 -- -- Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 -- -- Cash ...

Ferroptosis, a regulated cell death mechanism, is emerging as a promising target for cancer therapy. The process is mediated by the activity of acyl-CoA synthetase family member 4 (ACSL4) protein.